Episode Details

Back to Episodes
Can One Tiny Glaucoma Implant Replace Years of Eye Drops? New Randomized iDose TR Results

Can One Tiny Glaucoma Implant Replace Years of Eye Drops? New Randomized iDose TR Results

Published 1 month ago
Description

This audio article is from VisualFieldTest.com.

Read the full article here: https://visualfieldtest.com/en/can-one-tiny-glaucoma-implant-replace-years-of-eye-drops-new-randomized-idose-tr-results

Test your visual field online: https://visualfieldtest.com

Support the show so new episodes keep coming: https://www.buzzsprout.com/2563091/support

Excerpt:

Can One Tiny Glaucoma Implant Replace Years of Eye Drops? New Randomized iDose TR Results A small randomized trial reported a sizeable pressure reduction when iDose TR was added to cataract surgery: at three months, the combination group’s average daytime eye pressure fell by 11.1 millimeters of mercury, compared with 7.4 millimeters after cataract surgery alone. The company-reported difference between groups was 3.6 millimeters of mercury. That comparison is the key result: because both groups had cataract surgery, it estimates the extra short-term reduction associated with adding iDose TR in this trial setting. But the public results are only a topline report. They do not provide the starting pressures, final average pressures, confidence intervals, responder percentages, or enough detail to separate the effect of cataract surgery from medication washout and other baseline changes. Nor do they show whether the additional reduction lasts one or three years. Bottom line: iDose TR may reduce the need for daily drops for some people. The new trial supports an additional pressure-lowering effect at three months, but it does not yet show that an implant every few years can replace all drops—or postpone laser or glaucoma surgery over the long term. The Phase 4 results were announced on October 9, 2026. As of October 15, 2026, the results were available as a company-released topline report, not a full peer-reviewed publication. (Glaukos/Business Wire release) () What GLK-101-04 tested GLK-101-04 was a Phase 4 trial comparing iDose TR implanted during cataract surgery with cataract surgery alone. The official trial registry number is NCT06848946. (ClinicalTrials.gov record) () For the full table, please open this article on visualfieldtest.com. The public registry gives only a limited account of eligibility. It lists active corneal inflammation or swelling and certain retinal disorders as exclusions. It does not report the trial’s glaucoma-severity distribution, baseline visual-field damage, or the prior laser and surgery history of the participants in the topline announcement. (ClinicalTrials.gov record) () What is not public yet The topline release and registry do not provide the following information for GLK-101-04: Medicated starting pressure and unmedicated starting pressure. Whether pressure-lowering medicines were washed out before baseline, and, if so, how. How many participants used one or more glaucoma medicines before the trial. Detailed prior treatment history, such as selective laser trabeculoplasty or earlier glaucoma surgery. How many participants had mild, moderate, or advanced glaucoma. The group’s final average pressure at Month 3. Exact responder rates at reductions of 20%, 30%, or 40%. The percentages reaching pressure thresholds of 18, 15, 12, or 10 millimeters of mercury. The treatment difference’s confidence interval or standard deviation. A related earlier study of iDose TR used pressure-lowering medicine washout, but that does not establish that GLK-101-04 used the same rules. The new trial’s own public information is insufficient to confirm washout or reconstruct its baseline pressure. (Earlier iDose TR phase 3 report) () What the three-month results do—and do not—tell us The company reported mean daytime pressure reductions from baseline of: 11.1 millimeters

Listen Now

Love PodBriefly?

If you like Podbriefly.com, please consider donating to support the ongoing development.

Support Us